A 2011 whistleblower complaint that was unsealed on January 20 of this year alleges that Forest Pharmaceuticals bribed a principle investigator of the STAR*D (Sequenced Treatment to Relieve Depression) study to fix the results in favor of the company’s drug Celexa. The complaint alleges that because of this bribe, Celexa was the only antidepressant employed in the first part of the study, and also led to falsification and overstatement of the drug’s effectiveness. The whistleblower is Ed Pigott, who has blogged on the STAR*D trial for madinamerica.com.
Read more Discuss →
Mad in America hosts blogs by a diverse group of writers. These posts are designed to serve as a public forum for a discussion—broadly speaking—of psychiatry and its treatments. The opinions expressed are the writers’ own.